Indaptus Therapeutics (INDP) Accumulated Expenses (2020 - 2026)

Indaptus Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $43075.0 for Q1 2026.

• In Q1 2026, Accumulated Expenses fell 48.39% year-over-year to $43075.0; the TTM figure through Mar 2026 stood at $43075.0 (down 48.39% YoY), while the FY2025 annual figure was $4.0 million, up 21.62% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $43075.0, down from $4.0 million in the prior quarter.
• The five-year high for Accumulated Expenses was $4.0 million in Q4 2025, with the low at $43075.0 in Q1 2026.
• The 5-year median for Accumulated Expenses is $795183.0 (2023), against an average of $1.2 million.
• The sharpest annual moves came in 2024 and 2025: Accumulated Expenses jumped 238.77% in 2024, then plunged 95.38% in 2025.
• Indaptus Therapeutics' Accumulated Expenses stood at $1.2 million in 2022, then fell by 0.26% to $1.2 million in 2023, then jumped by 172.84% to $3.3 million in 2024, then rose by 21.62% to $4.0 million in 2025, then sank by 98.93% to $43075.0 in 2026.
• Business Quant data shows INDP's Accumulated Expenses at $43075.0 in Q1 2026, $4.0 million in Q4 2025, and $43389.0 in Q3 2025.